Updates on LI‐RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI
Journal of Magnetic Resonance Imaging · 2023
DOI: 10.1002/jmri.28659 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Magnetic Resonance Imaging, 2023. Verfasst von Richa Patel und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Stanford, California, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
As the incidence of hepatocellular carcinoma (HCC) and subsequent treatments with liver‐directed therapies rise, the complexity of assessing lesion response has also increased. The Liver Imaging Reporting and Data Systems (LI‐RADS) treatment response algorithm (LI‐RADS TRA) was created to standardize the assessment of response after locoregional therapy (LRT) on contrast‐enhanced CT or MRI. Originally created based on expert opinion, these guidelines are currently undergoing revision based on emerging evidence. While many studies support the use of LR‐TRA for evaluation of HCC response after thermal ablation and intra‐arterial embolic therapy, data suggest a need for refinements to improve assessment after radiation therapy. In this manuscript, we review expected MR imaging findings after different forms of LRT, clarify how to apply the current LI‐RADS TRA by type of LRT, explore emerging literature on LI‐RADS TRA, and highlight future updates to the algorithm. Evidence Level 3. Technical Efficacy Stage 2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Stanford, California, USA.
- Department of Radiology, University of Michigan Medicine, Ann Arbor, Michigan, USA.
- Department of Internal Medicine, University of Michigan Medicine, Ann Arbor, Michigan, USA.
- Department of Radiology, University of Toledo Medical Center, Toledo, Ohio, USA.
- Department of Radiology and Hepatology, University of Michigan Medicine, Michigan, USA.
- Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA.
ORCID-Profile: Richard Kinh Gian Do, Mishal Mendiratta-Lala
Förderung
- NCI NIH HHS
Zitieren
APA
Patel, R., Aslam, A., Parikh, N. D., Mervak, B., Mubarak, E., Higgins, L., Lala, K., Conner, J. F., Khaykin, V., Bashir, M., Do, R. K. G., Burke, L. M. B., Smith, E. N., Kim, C. Y., Shampain, K. L., Owen, D., & Mendiratta-Lala, M. (2023). Updates on LI‐RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI. Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.28659
Vancouver
Patel R, Aslam A, Parikh ND, Mervak B, Mubarak E, Higgins L, et al. Updates on LI‐RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI. Journal of Magnetic Resonance Imaging. 2023. doi:10.1002/jmri.28659
BibTeX
@article{Patel2023,
author = {Patel, Richa and Aslam, Anum and Parikh, Neehar D and Mervak, Benjamin and Mubarak, Eman and Higgins, Lily and Lala, Kayli and Conner, Jack F and Khaykin, Valerie and Bashir, Mustafa and Do, Richard Kinh Gian and Burke, Lauren M B and Smith, Elainea N and Kim, Charles Y and Shampain, Kimberly L and Owen, Dawn and Mendiratta-Lala, Mishal},
title = {Updates on LI‐RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI},
journal = {Journal of Magnetic Resonance Imaging},
year = {2023},
doi = {10.1002/jmri.28659}
}
EUVIMED